Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
A phase 3 trial finds recombinant human TSH non-inferior to thyroid hormone withdrawal for radioiodine ablation in intermediate-risk thyroid cancer, with fewer adverse events. PICO summary and commentary.
An open-label phase 3 noninferiority trial finds recombinant human thyrotropin matches thyroid hormone withdrawal for radioactive iodine ablation success in intermediate-risk differentiated thyroid cancer, with fewer adverse events. PICO summary and expert commentary.
Pooled RCTs find mild sleep restriction lowers TSH in women specifically, with no effect overall and no change in FT4. PICO summary and expert commentary.
A phase 2b randomized trial found that cotadutide reduced urinary albumin-to-creatinine ratio versus placebo in type 2 diabetes with chronic kidney disease, a surrogate signal requiring confirmation. PICO summary and expert commentary.
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.
A single-centre randomized trial testing an integrated data platform plus dietary management against routine care in 180 adults with type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN 6 reports lower odds of new-onset diabetic kidney disease with semaglutide versus placebo in people with type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
